COMMITMENTS AND CONTINGENCIES - Haisco Pharmaceuticals License Agreement (Details) - USD ($) |
3 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Jun. 22, 2026 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Jul. 31, 2026 |
Dec. 31, 2025 |
|
| COMMITMENTS AND CONTINGENCIES | |||||||
| Research and development expense | $ 27,370,000 | $ 5,774,000 | $ 36,160,000 | $ 13,067,000 | |||
| Transaction costs in connection with acquisition | $ 0 | ||||||
| Contingent liabilities | $ 0 | $ 0 | $ 0 | ||||
| Haisco Agreement | |||||||
| COMMITMENTS AND CONTINGENCIES | |||||||
| Non refundable payment | $ 20,000,000 | ||||||
| Change of control contingency period | 18 months | ||||||
| Research and development expense | $ 20,000,000 | ||||||
| Haisco Agreement | Maximum | |||||||
| COMMITMENTS AND CONTINGENCIES | |||||||
| Contingent payment | $ 1,400,000,000 | ||||||
| X | ||||||||||
- Definition The period following the execution of the License Agreement during which a change of control triggers a payment obligation based on a low double-digit percentage of the fair market value of the licensed rights. No definition available.
|
| X | ||||||||||
- Definition Amount of contingent milestone payments under collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition The amount of upfront payments under collaboration arrangement. No definition available.
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|